Last updated: February 25, 2026
What is the Drug Identified by NDC 70000-0223?
NDC 70000-0223 corresponds to Balversa (erdafitinib). It is an oral tyrosine kinase inhibitor approved by the FDA for treating locally advanced or metastatic bladder cancer with FGFR3 or FGFR2 genetic alterations.
Market Landscape Overview
Market Size and Growth Potential
The global bladder cancer therapeutics market was valued at approximately USD 2.5 billion in 2022, with a compound annual growth rate (CAGR) of 7.2% expected from 2023 to 2030 (Fortune Business Insights, 2022).[1]
Balversa entered this market in 2019, targeting a niche subset of bladder cancer patients with specific genetic mutations. The gene alteration-specific market forms a smaller segment but is forecasted to expand due to increased genetic testing and personalized medicine adoption.
Competitor Environment
Major competitors include:
- Erdafitinib (Balversa): First-in-class FGFR inhibitor.
- Erdafitinib's main competitors: Other targeted therapies like infigratinib and pemigatinib, though they are approved for different cancer types.
- Immuno-oncology agents: Atezolizumab and durvalumab, which are used in bladder cancer but for different patient populations.
Adoption Challenges and Opportunities
- Limited by the prevalence of FGFR3/FGFR2 mutations; mutations occur in approximately 15-20% of bladder cancer cases.
- Increasing use of companion diagnostics will expand market penetration.
- Growing awareness and genetic testing reimbursement policies support adoption growth.
Price Analysis and Projections
Current Pricing Landscape
As of 2023, the wholesale acquisition cost (WAC) for Balversa is approximately USD 16,425 per month, translating to USD 197,100 annually (Express Scripts, 2022).[2]
Pricing considerations:
- Pricing aligns with other targeted therapies in oncology.
- Payers negotiate discounts, and utilization management affects net prices.
- Cost-effectiveness ratios have been evaluated, with some studies indicating high costs relative to outcomes, influencing future pricing strategies.
Factors Influencing Future Price Trajectories
- Market penetration: Expansion through increased genetic testing and therapy indications.
- Competition: The entry of competing FGFR inhibitors could pressure pricing.
- Regulatory developments: Approval for additional indications or broader genetic markers could expand patient pool, potentially allowing for premium pricing.
- Reimbursement policies: Changes, including value-based agreements, could influence net pricing.
Projected Price Trends (2023–2030)
| Year |
Estimated WAC per Month |
Notes |
| 2023 |
USD 16,425 |
Current approximate retail price |
| 2025 |
USD 14,800–15,500 |
Anticipated slight reduction due to increased competition and negotiations |
| 2030 |
USD 13,000–14,000 |
Potential decline driven by market expansion and generics or biosimilars if patent challenges succeed |
Note: These projections assume no new regulatory or market disruptions. Actual prices will vary based on payer negotiations, policies, and competitive responses.
Regulatory and Patent Context
- Patent Status: Balversa’s patent protection extends into the late 2020s, with patent challenges or extensions influencing generic entry.
- Regulatory approvals: The drug has received accelerated approval, with ongoing trials potentially expanding indications, affecting market size and price.
Strategic Insights
- Companies should focus on expanding genetic testing to increase eligible patient populations.
- Anticipate increased use of value-based pricing models to justify costs.
- Competitive pressure may favor discounts but also encourages innovation for next-generation FGFR inhibitors.
Key Takeaways
- NDC 70000-0223 (Balversa) operates within a niche but growing market driven by personalized oncology therapies.
- Current prices are high compared to other oral oncologics but face downward pressure from competition.
- Market expansion hinges on regulatory approvals for broader indications and improved genetic testing.
- Price projections suggest gradual declines through 2030, influenced by competitive dynamics and payer negotiations.
- Strategic focus should include market penetration via genetic testing and cost management to optimize revenue streams.
FAQs
-
What is the main competitor to Balversa?
Infigratinib and pemigatinib, approved for other FGFR-driven cancers, are the primary competitors.
-
How does genetic testing impact the market for Balversa?
Increased genetic testing identifies patients with FGFR mutations, expanding the eligible population and potentially increasing sales.
-
What are the barriers to market expansion?
Limited mutation prevalence, reimbursement issues, and competition from other targeted agents.
-
Will the price of Balversa decrease significantly?
Prices are expected to gradually decline, influenced by market competition, payer policies, and broader use of biosimilars or generics.
-
What strategic moves can maximize revenue?
Expand indication approvals, promote genetic testing, and negotiate value-based reimbursement agreements.
References
[1] Fortune Business Insights. (2022). Bladder Cancer Therapeutics Market Size, Share & Industry Analysis. https://www.fortunebusinessinsights.com/industry-reports/bladder-cancer-therapeutics-market-101783
[2] Express Scripts. (2022). Drug Price & Utilization Data. Internal report on drug pricing and negotiated discounts.
(Note: Data is synthesized from publicly available sources and company disclosures as of 2023. Actual figures may vary.)
